Recombinant SARS-CoV-2 Spike RBD (B.1.1.529/Omicron) protein C-6His

Recombinant SARS-CoV-2 S protein RBD Protein is produced by our Mammalian expression system and the target gene encoding Arg319-Phe541 (G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H) is expressed with a 6His tag at the C-terminus. G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y and Y505H mutations were identified in the SARS-CoV-2 variant (known as Omicron/B.1.1.529 lineage) which emerged in South Africa.

SARS-CoV-2 RBD Protein, SARS-CoV-2 Spike RBD Protein, SARS-CoV-2 S Protein RBD

SARS-CoV-2

Mammalian

26.2kDa AP Mol Mass: 32-40kDa, reducing conditions

Supplied as a 0.2 μm filtered solution of PBS, pH 7.4

Arg319-Phe541

C-6His

Affinity purification chromatography

 Greater than 95% as determined by reducing SDS-PAGE.

Less than 1 EU per μg by the LAL method.

unconjugated

6 months from date of receipt,-20℃ to -70℃ as supplied.avoid repeated freeze-thaw cycles.

The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.